1. PolyPid's NDA for D-PLEX100 set for submission in early 2026. 2. FDA supports NDA submission based on Phase 3 clinical data. 3. D-PLEX100 targets surgical site infection prevention in colorectal surgeries. 4. The drug shows significant SSI reduction, leading to Breakthrough Therapy designation. 5. Positive FDA feedback strengthens PolyPid's regulatory strategy and market prospects.
FAQ
Why Bullish?
Positive FDA feedback and anticipated NDA submission could drive increased investor interest. Historical examples include similar outcomes leading to stock price surges in biotech firms.
How important is it?
The drug's potential market impact coupled with FDA validation makes this news highly relevant and impactful.
Why Long Term?
The expected NDA submission and regulatory progress can enhance market positioning long-term. Past cases, like with Gilead Sciences, show sustained price growth following successful applications.
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100
PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company focused on enhancing surgical outcomes, has reported favorable feedback from the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for D-PLEX100. This product candidate aims to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgeries.
FDA Supports NDA Submission for D-PLEX100
The recent pre-NDA meeting with the FDA confirmed that PolyPid's clinical data package, particularly results from the Phase 3 SHIELD II trial, is deemed adequate to support the NDA submission. Furthermore, the FDA has allowed a rolling review of the NDA, which enables PolyPid to submit initial sections starting in early 2026.
According to the company, the FDA's positive response has eliminated the need for an in-person meeting that was scheduled for December 3, 2025. Dikla Czaczkes Akselbrad, CEO of PolyPid, expressed satisfaction with the regulatory agency's collaborative approach, stating, "We are pleased with the pre-NDA meeting feedback we received from the FDA, which confirmed agreement on the content and format for our planned NDA submission."
Overview of D-PLEX100
D-PLEX100 is designed to provide prolonged and controlled local antibacterial activity at the surgical site, effectively preventing SSIs. The product utilizes PLEX (Polymer-Lipid Encapsulation matriX) technology paired with active pharmaceutical ingredients, allowing for an extended release of the broad-spectrum antibiotic doxycycline.
Key highlights of D-PLEX100 include:
- Extended Release: Provides a high local concentration of doxycycline for up to 30 days.
- Proven Efficacy: Achieved a statistically significant 58% relative risk reduction in SSI incidence (p<0.005) in the Phase 3 SHIELD II trial.
- Breakthrough Therapy Designation: Received from the FDA for the prevention of SSIs in elective colorectal surgery.
About PolyPid Ltd.
PolyPid (Nasdaq: PYPD) is at the forefront of biopharmaceutical innovation, striving to enhance surgical outcomes through controlled-release therapeutics. With its proprietary PLEX technology, the company is dedicated to ensuring optimal drug delivery at effective release rates over extended periods. In addition to D-PLEX100, PolyPid is advancing an innovative pipeline that includes treatments for oncology, obesity, and diabetes.
Forward-Looking Statements
This announcement contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act and other applicable laws. These statements rely on management's current expectations and beliefs regarding the NDA submission and the adequacy of clinical data. There are inherent uncertainties that could cause actual results to differ materially from those anticipated.
For more detailed information regarding the potential risks and uncertainties, stakeholders are encouraged to review PolyPid's reports filed with the Securities and Exchange Commission, including the risks noted in the Company’s Annual Report on Form 20-F from February 26, 2025.
Contact Information
For further inquiries, please contact:
- Ori Warshavsky, 908-858-5995, IR@polypid.com
- Arx Investor Relations, North American Equities Desk, polypid@arxhq.com